Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
26.04.24
20:43 Uhr
24,600 Euro
-0,020
-0,08 %
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
24,37024,56021:24
24,38024,60021:04

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20:36Bristol, Sanofi, Takeda gain positive CHMP recommendations2
15:18Takeda Reports Positive CHMP Opinion For Fruquintinib162BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Takeda (TAK) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of fruquintinib, a selective...
► Artikel lesen
14:36HUTCHMED (China) Limited: HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda63- If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade - - Positive opinion based...
► Artikel lesen
14:10Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB11
12:10Fierce Pharma Asia-Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu nears key readout11
DoTakeda said to have left industry trade group BIO4
DiNeurocrine succeeds in mid-stage trial for Takeda-partnered depression drug11
DiNeurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail8
DiTakeda's subcutaneous Entyvio approved by FDA as Crohn's disease maintenance therapy3
DiTakeda, Astellas & Sumitomo Mitsui Form Joint Venture to Lift Japanese Innovation From 'Valley of Death'6
MoTakeda and Astellas Agree to Establish Joint Venture Company4
MoTakeda investiert 5 Millionen Franken in Solaranlage6
MoTakeda and others sign agreement to form early drug discovery incubation JV3
MoTakeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programs264TOKYO (dpa-AFX) - Takeda Pharmaceutical Co. Ltd. (TAK), Astellas Pharma Inc. (ALPMY), and Sumitomo Mitsui Banking Corp. announced Monday that they have signed a master agreement to establish...
► Artikel lesen
MoAstellas Pharma Inc.: Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs72TOKYO, April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and...
► Artikel lesen
19.04.Fierce Pharma Asia-Leqembi's cost to Medicare; Takeda's $1.2B-plus Kumquat deal; Fujifilm Diosynth's reorg6
19.04.FDA approves Takeda's ENTYVIO SC for Crohn's disease4
19.04.FDA Approves Subcutaneous Administration Of Takeda's Entyvio For Crohn's Disease362TOKYO (dpa-AFX) - Takeda (TAK) said that the U.S. Food and Drug Administration has approved Entyvio (vedolizumab) subcutaneous administration for maintenance therapy in adults with moderately...
► Artikel lesen
19.04.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::FDA APPROVES SC ADMINISTRATION OF ENTYVIO - MAINTENANCE THERAPY IN MODERATELY TO SEVERELY ACTIVE CD2
18.04.Takeda gains rights to Kumquat's immune-oncology programme in deal worth over $1.2bn5
Seite:  Weiter >>
233 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1